Issue 3, 2016
From the journal:

MedChemComm

Correction: eCF309: a potent, selective and cell-permeable mTOR inhibitor

Craig Fraser,a   Neil O. Carraghera  and  Asier Unciti-Broceta*a  

* Corresponding authors

a Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK
E-mail: Asier.Unciti-Broceta@igmm.ed.ac.uk

Abstract

Correction for ‘eCF309: a potent, selective and cell-permeable mTOR inhibitor’ by Craig Fraser et al., MedChemComm, 2016, DOI: 10.1039/c5md00493d.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/C6MD90009G
Article type
Correction
Submitted
22 Feb 2016
Accepted
22 Feb 2016
First published
29 Feb 2016
This article is Open Access
Creative Commons BY license

Med. Chem. Commun., 2016,7, 562-562

Permissions

Request permissions

Correction: eCF309: a potent, selective and cell-permeable mTOR inhibitor

C. Fraser, N. O. Carragher and A. Unciti-Broceta, Med. Chem. Commun., 2016, 7, 562 DOI: 10.1039/C6MD90009G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements